Medical experts and patients are invited to attend the International Pompe Conference 2003. The goal of the conference is to bring together scientific expertise and patients’ experience. On the way towards a therapy for Pompe’s Disease there were and are many examples...

Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has treated the first patient in a pivotal clinical trialA research study that tests new treatments or approaches in people. evaluating the use of its MyozymeTM recombinant human acid alpha-glucosidase enzymeA protein that helps the body carry out chemical reactions. (rhGAA) as a potential treatment for...

CAMBRIDGE, Mass – Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has begun enrolment in a clinical trial evaluating the use of its Myozyme™  recombinant human acid alpha -Glucosidase enzyme as a potential treatment for Pompe...

An update by Genzyme regarding treatment for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart.. Q: What is the status of the Pompe program? Genzyme has made strong progress within its Pompe disease program since its decision earlier this year to move forward with an internally developed product...

IBaarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone conference of September 24 2002. We discussed issues concerning the production, the transition, new trials and the meeting with the Erasmus University, VSN,...

In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzyme) patients to the CHO derived product. Three of the nine patients (infantile patients in the Netherlands) will remain on the transgenic enzyme until April 2003, when supply will be...

Board members of the IPA, the International Pompe Association, met with key representatives of Genzyme in Cambridge, Massachusetts on April 16-17, 2002.  The IPA members in attendance were: Randall House, AMDA-US; Marylyn House, AMDA-US, Ria Broekgaarden, VSN-The...

Excerpt From Genzyme’s April 17, 2002 Press Release Pompe Update Genzyme is moving forward aggressively with its program to develop an effective therapy for Pompe disease. Genzyme has invested significant resources over the past four years pursuing the most promising...

Following is a letter sent to the IPA by Jan van Heek, Executive Vice President of Genzyme, for release prior to the VSN Pompe Patient Conference which took place on March 9, 2002. in the Netherlands. Dear Friends, On Saturday, March 9th, 2002, I will be speaking at...

The first official IPA Board Meeting occurred in Rotterdam, The Netherlands on Feb. 18-19, 2002. Future agendas were planned and the following committees were formed. Communications—Kevin O’Donnell, Alan Muir, Marylyn House Patient Organizations—Maryze Schoneveld,...